AVITA MEDICAL INC (RCEL) Stock Price, Quote, News and Overview
NASDAQ:RCEL - Nasdaq - US05380C1027 - Common Stock - Currency: USD
RCEL Quote, Performance and Key Statistics
9.95
-0.27 (-2.64%)
The current stock price of RCEL is 9.95 USD. In the past month the price increased by 17.33%. In the past year, price decreased by -41.81%.
RCEL Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.85 | 354.98B | ||
| AMGN | AMGEN INC | 15.03 | 159.99B | ||
| GILD | GILEAD SCIENCES INC | 23.87 | 137.10B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1656.31 | 123.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.25 | 76.09B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.34B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.37B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.26B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.06B | ||
| NTRA | NATERA INC | N/A | 22.20B | ||
| BIIB | BIOGEN INC | 8.32 | 19.98B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.01B |
Related stock screener links
About RCEL
Company Profile
AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. The company is headquartered in Valencia California, California and currently employs 207 full-time employees. The company went IPO on 2012-03-18. The firm is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators. RECELL is used for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. The platform technology of the RECELL System enables a thin split-thickness skin sample from the patient to be processed and prepared, producing an autologous cellular suspension called Spray-On Skin Cells. These Spray-On Skin Cells are prepared at the point of care in as little as 30 minutes, providing a new way to treat thermal burn wounds and full-thickness skin defects.
Company Info
AVITA MEDICAL INC
28159 Avenue Stanford, Suite 220
Valencia California CALIFORNIA 91355 US
CEO: Michael Perry
Employees: 207
Company Website: https://www.avitamedical.com/
Investor Relations: https://ir.avitamedical.com/
Phone: 16613679170
AVITA MEDICAL INC / RCEL FAQ
What is the stock price of AVITA MEDICAL INC today?
The current stock price of RCEL is 9.95 USD. The price decreased by -2.64% in the last trading session.
What is the ticker symbol for AVITA MEDICAL INC stock?
The exchange symbol of AVITA MEDICAL INC is RCEL and it is listed on the Nasdaq exchange.
On which exchange is RCEL stock listed?
RCEL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AVITA MEDICAL INC stock?
14 analysts have analysed RCEL and the average price target is 17.14 USD. This implies a price increase of 72.22% is expected in the next year compared to the current price of 9.95. Check the AVITA MEDICAL INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AVITA MEDICAL INC worth?
AVITA MEDICAL INC (RCEL) has a market capitalization of 260.89M USD. This makes RCEL a Micro Cap stock.
How many employees does AVITA MEDICAL INC have?
AVITA MEDICAL INC (RCEL) currently has 207 employees.
What are the support and resistance levels for AVITA MEDICAL INC (RCEL) stock?
AVITA MEDICAL INC (RCEL) has a support level at 8.78 and a resistance level at 10.17. Check the full technical report for a detailed analysis of RCEL support and resistance levels.
Is AVITA MEDICAL INC (RCEL) expected to grow?
The Revenue of AVITA MEDICAL INC (RCEL) is expected to grow by 53.51% in the next year. Check the estimates tab for more information on the RCEL EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy AVITA MEDICAL INC (RCEL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RCEL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RCEL, evaluating the profitability, health, valuation and growth aspects
- AVITA MEDICAL INC (RCEL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AVITA MEDICAL INC (RCEL) Sales and EPS estimates to see what analysts future expectations are.
- AVITA MEDICAL INC (RCEL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AVITA MEDICAL INC (RCEL) Insider and Institutional Ownership to learn about the owners and their transactions.
- AVITA MEDICAL INC (RCEL) Stock Chart to make your own analysis
- AVITA MEDICAL INC (RCEL) Latest news and press-releases to stay up to date.
Does AVITA MEDICAL INC (RCEL) stock pay dividends?
RCEL does not pay a dividend.
When does AVITA MEDICAL INC (RCEL) report earnings?
AVITA MEDICAL INC (RCEL) will report earnings on 2025-05-12, after the market close.
What is the Price/Earnings (PE) ratio of AVITA MEDICAL INC (RCEL)?
AVITA MEDICAL INC (RCEL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.39).
What is the Short Interest ratio of AVITA MEDICAL INC (RCEL) stock?
The outstanding short interest for AVITA MEDICAL INC (RCEL) is 6.97% of its float. Check the ownership tab for more information on the RCEL short interest.
RCEL Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to RCEL. When comparing the yearly performance of all stocks, RCEL is a bad performer in the overall market: 92.06% of all stocks are doing better.
RCEL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RCEL. Both the profitability and financial health of RCEL have multiple concerns.
RCEL Financial Highlights
Over the last trailing twelve months RCEL reported a non-GAAP Earnings per Share(EPS) of -2.39. The EPS decreased by -70.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -77.59% | ||
| ROE | -1374.64% | ||
| Debt/Equity | 9.39 |
RCEL Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 77% to RCEL. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of 71.22% and a revenue growth 53.51% for RCEL